Terms: = Lymphoma AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
16 results:
1. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
2. Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer.
Honkanen TJ; Luukkainen MEK; Koivunen JP
Cancer Biol Ther; 2023 Dec; 24(1):2256906. PubMed ID: 37722715
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract] [Full Text] [Related]
4. Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin lymphoma.
Jhawar SR; Rivera-Núñez Z; Drachtman R; Cole PD; Hoppe BS; Parikh RR
JAMA Oncol; 2019 May; 5(5):689-695. PubMed ID: 30605220
[TBL] [Abstract] [Full Text] [Related]
5. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
[TBL] [Abstract] [Full Text] [Related]
6. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
Dong X; Fernandez-Salas E; Li E; Wang S
Neoplasia; 2016 Mar; 18(3):162-71. PubMed ID: 26992917
[TBL] [Abstract] [Full Text] [Related]
7. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract] [Full Text] [Related]
8. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells.
Grabinski N; Ewald F
Invest New Drugs; 2014 Dec; 32(6):1096-104. PubMed ID: 25081321
[TBL] [Abstract] [Full Text] [Related]
9. Α-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/her3 signaling.
Zhuo RJ; Wang F; Zhang XH; Zhang JJ; Xu J; Dong W; Zou ZQ
Mol Med Rep; 2014 Mar; 9(3):993-8. PubMed ID: 24425042
[TBL] [Abstract] [Full Text] [Related]
10. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
Cao XX; Li J; Zhang W; Duan MH; Shen T; Zhou DB
Ann Hematol; 2014 Jun; 93(6):1001-5. PubMed ID: 24408160
[TBL] [Abstract] [Full Text] [Related]
11. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract] [Full Text] [Related]
12. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract] [Full Text] [Related]
13. [The assessment of temperament, quality of life and intensity of depressive symptoms in patients with Hodgkin's disease in different stages of the illness].
Kawiecka-Dziembowska B; Borkowska A; Zurawski B; Pałaszyńska R; Makarewicz R
Psychiatr Pol; 2005; 39(4):679-90. PubMed ID: 16237973
[TBL] [Abstract] [Full Text] [Related]
14. Primary lymphoma of bone.
Luna-Ortiz K; Cervera-Ceballos E; Dominguez-Malagon H; Labardini-Mendez J; De la Garza-Salazar J; Herrera-Gomez A; Barrera-Franco JL
Rev Invest Clin; 2003; 55(5):502-6. PubMed ID: 14968470
[TBL] [Abstract] [Full Text] [Related]
15. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea.
Bruchova H; Borovanova T; Klamova H; Brdicka R
Leuk Lymphoma; 2002 Jun; 43(6):1289-95. PubMed ID: 12152998
[TBL] [Abstract] [Full Text] [Related]
16. [Diagnosis and treatment of 31 patients with splenic tumors].
Chen Y; Huang Z; Feng Y
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):510-2. PubMed ID: 11859725
[TBL] [Abstract] [Full Text] [Related]